Neumora Therapeutics (NMRA) Earnings Date, Estimates & Call Transcripts $10.85 +0.35 (+3.33%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Neumora Therapeutics Latest Earnings SummaryActual EPS (Nov. 12) -$0.45 Missed By -$0.06 Consensus EPS (Nov. 12) -$0.39 Neumora Therapeutics announced Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.45, which missed the consensus estimate of -$0.39 by $0.06. With a trailing EPS of -$1.87, Neumora Therapeutics' earnings are expected to grow next year, from ($1.61) to ($1.60) per share. Conference CallConference Call TranscriptPowered by Get Neumora Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neumora Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNMRA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NMRA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Neumora Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$1.56-$1.56-$1.56Q2 20241-$1.59-$1.59-$1.59Q3 20242-$0.38-$0.33-$0.36Q4 20242-$0.46-$0.46-$0.46FY 20246-$3.99-$3.94-$3.97Q1 20252-$0.47-$0.46-$0.47Q2 20252-$0.48-$0.43-$0.46Q3 20252-$0.49-$0.43-$0.46Q4 20252-$0.50-$0.44-$0.47FY 20258($1.94)($1.76)($1.85) Neumora Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/12/2024Q3 2024-$0.39-$0.45 -$0.06-$0.45--8/6/2024Q2 2024-$0.37-$0.37--$0.37--5/7/2024Q1 2024-$0.34-$0.34--$0.34--3/7/2024Q4 2023-$0.76-$0.71+$0.05-$0.71--11/1/2023Q3 2023-$0.35-$1.14 -$0.79-$1.14-- Neumora Therapeutics Earnings - Frequently Asked Questions When did Neumora Therapeutics announce their last quarterly earnings? Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earning data on Tuesday, November 12, 2024. Learn more on NMRA's earnings history. Did Neumora Therapeutics beat their earnings estimates last quarter? In the previous quarter, Neumora Therapeutics (NASDAQ:NMRA) missed the analysts' consensus estimate of ($0.39) by $0.06 with a reported earnings per share (EPS) of ($0.45). Learn more on analysts' earnings estimate vs. NMRA's actual earnings. How can I listen to Neumora Therapeutics's earnings conference call? The conference call for Neumora Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Neumora Therapeutics's conference call transcript? The conference call transcript for Neumora Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Neumora Therapeutics generate each year? Neumora Therapeutics (NASDAQ:NMRA) has a recorded net income of -$235.93 million. NMRA has generated -$1.87 earnings per share over the last four quarters. What is Neumora Therapeutics's EPS forecast for next year? Neumora Therapeutics's earnings are expected to grow from ($1.61) per share to ($1.60) per share in the next year. More Earnings Resources from MarketBeat Related Companies Halozyme Therapeutics Earnings Krystal Biotech Earnings Arcellx Earnings ADMA Biologics Earnings Immunovant Earnings Scholar Rock Earnings CRISPR Therapeutics Earnings Denali Therapeutics Earnings Twist Bioscience Earnings Vericel Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover This page (NASDAQ:NMRA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
